RET原癌基因与非小细胞肺癌的研究现状

doi:10.3760/cma.j.cn371439-20241115-00039

摘要/Abstract

摘要：

RET原癌基因编码的RET蛋白是一种受体酪氨酸激酶，可作为非小细胞肺癌（NSCLC）潜在的治疗靶点。在NSCLC中，RET融合变异发生率为1%~2%，多见于年轻、不吸烟患者。传统化疗、免疫治疗和多靶点激酶抑制剂在RET融合NSCLC患者中的疗效有限，但选择性RET抑制剂，如塞普替尼和普拉替尼，显著改善了此类患者的预后。选择性RET抑制剂耐药后的治疗策略是未来的研究方向。

关键词: 原癌基因蛋白质c-ret, 癌, 非小细胞肺, 分子靶向治疗

Abstract:

The RET protein encoded by RET proto-oncogene is a receptor tyrosine kinase that serves as a potential therapeutic target in non-small cell lung cancer （NSCLC）. In NSCLC，the incidence of RET fusions variants ranges from 1%-2% and is more common in younger，non-smoking patients. Traditional chemotherapy，immunotherapy，and multitarget kinase inhibitors have shown limited efficacy in treating RET fusion-positive NSCLC patients. However，selective RET inhibitors，such as selpercatinib and pralsetinib，have significantly improved the prognosis of those patients. The treatment strategy following resistance to selective RET inhibitors is a future research direction.

Key words: Proto-oncogene proteins c-ret, Carcinoma, non-small-cell lung, Molecular targeted therapy

唐磊, 蔡宗佑, 常建华. RET原癌基因与非小细胞肺癌的研究现状[J]. 国际肿瘤学杂志, 2025, 52(4): 237-241.

Tang Lei, Cai Zongyou, Chang Jianhua. Research updates of RET proto-oncogene in non-small cell lung cancer[J]. Journal of International Oncology, 2025, 52(4): 237-241.

参考文献 45

[1]	Rodak O, Peris-Díaz MD, Olbromski M, et al. Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy[J]. Cancers (Basel), 2021, 13(18): 4705. DOI: 10.3390/cancers13184705.
[2]	Chevallier M, Borgeaud M, Addeo A, et al. Oncogenic driver mutations in non-small cell lung cancer: past, present and future[J]. World J Clin Oncol, 2021, 12(4): 217-237. DOI: 10.5306/wjco.v12.i4.217. pmid: 33959476
[3]	O'Leary C, Xu W, Pavlakis N, et al. Rearranged during transfection fusions in non-small cell lung cancer[J]. Cancers (Basel), 2019, 11(5): 620. DOI: 10.3390/cancers11050620.
[4]	Chen MF, Repetto M, Wilhelm C, et al. RET inhibitors in RET fusion-positive lung cancers: past, present, and future[J]. Drugs, 2024, 84(9): 1035-1053. DOI: 10.1007/s40265-024-02040-5. pmid: 38997570
[5]	Riely GJ, Wood DE, Ettinger DS, et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2024, 22(4): 249-274. DOI: 10.6004/jnccn.2204.0023.
[6]	Parimi V, Tolba K, Danziger N, et al. Genomic landscape of 891 RET fusions detected across diverse solid tumor types[J]. NPJ Precis Oncol, 2023, 7(1): 10. DOI: 10.1038/s41698-023-00347-2.
[7]	Lu C, Dong XR, Zhao J, et al. Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study[J]. J Hematol Oncol, 2020, 13(1): 37. DOI: 10.1186/s13045-020-00866-6.
[8]	Zhu YC, Wang WX, Zhang QX, et al. The KIF5B-RET fusion gene mutation as a novel mechanism of acquired EGFR tyrosine kinase inhibitor resistance in lung adenocarcinoma[J]. Clin Lung Cancer, 2019, 20(1): e73-e76. DOI: 10.1016/j.cllc.2018.09.011.
[9]	Hess LM, Han Y, Zhu YE, et al. Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States[J]. BMC Cancer, 2021, 21(1): 28. DOI: 10.1186/s12885-020-07714-3.
[10]	Feng J, Li Y, Wei B, et al. Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients[J]. Transl Lung Cancer Res, 2022, 11(4): 617-631. DOI: 10.21037/tlcr-22-202.
[11]	Shen T, Pu X, Wang L, et al. Association between RET fusions and efficacy of pemetrexed-based chemotherapy for patients with advanced NSCLC in China: a multicenter retrospective study[J]. Clin Lung Cancer, 2020, 21(5): e349-e354. DOI: 10.1016/j.cllc.2020.02.006.
[12]	Dantoing E, Piton N, Salaün M, et al. Anti-PD1/PD-L1 immunotherapy for non-small cell lung cancer with actionable oncogenic driver mutations[J]. Int J Mol Sci, 2021, 22(12): 6288. DOI: 10.3390/ijms22126288.
[13]	Liang W, Guo M, Pan Z, et al. Association between certain non-small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-ligand 1 inhibition[J]. Cancer Sci, 2019, 110(6): 2014-2021. DOI: 10.1111/cas.14032.
[14]	Guisier F, Dubos-Arvis C, Viñas F, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or Met mutations or RET translocation: GFPC 01-2018[J]. J Thorac Oncol, 2020, 15(4): 628-636. DOI: 10.1016/j.jtho.2019.12.129.
[15]	Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry[J]. Ann Oncol, 2019, 30(8): 1321-1328. DOI: 10.1093/annonc/mdz167. pmid: 31125062
[16]	Knetki-Wróblewska M, Wojas-Krawczyk K, Kowalski DM, et al. Non-small-cell lung cancer patients with coexistence of high PD-L1 expression and RET fusion-which path should we follow? Case reports and literature review[J]. J Clin Med, 2022, 11(6): 1630. DOI: 10.3390/jcm11061630.
[17]	Offin M, Guo R, Wu SL, et al. Immunophenotype and response to immunotherapy of RET-rearranged lung cancers[J]. JCO Precis Oncol, 2019, 3: PO. 18.00386. DOI: 10.1200/PO.18.00386.
[18]	Aldea M, Marinello A, Duruisseaux M, et al. RET-MAP: an international multicenter study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion[J]. J Thorac Oncol, 2023, 18(5): 576-586. DOI: 10.1016/j.jtho.2022.12.018.
[19]	谢红霞, 左金辉, 廖冬颖, 等. PD-L1抑制剂在非小细胞肺癌中的应用[J]. 国际肿瘤学杂志, 2022, 49(2): 111-115. DOI: 10.3760/cma.j.cn371439-20210121-00018.
[20]	Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial[J]. Lancet Oncol, 2016, 17(12): 1653-1660. DOI: 10.1016/S1470-2045(16)30562-9. pmid: 27825636
[21]	Lee SH, Lee JK, Ahn MJ, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase Ⅱ clinical trial[J]. Ann Oncol, 2017, 28(2): 292-297. DOI: 10.1093/annonc/mdw559. pmid: 27803005
[22]	Hida T, Velcheti V, Reckamp KL, et al. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma[J]. Lung Cancer, 2019, 138: 124-130. DOI: 10.1016/j.lungcan.2019.09.011. pmid: 31710864
[23]	Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(9): 813-824. DOI: 10.1056/NEJMoa2005653.
[24]	Subbiah V, Gainor JF, Oxnard GR, et al. Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial[J]. Clin Cancer Res, 2021, 27(15): 4160-4167. DOI: 10.1158/1078-0432.CCR-21-0800. pmid: 34088726
[25]	Minchom A, Tan AC, Massarelli E, et al. Patient-reported outcomes with selpercatinib among patients with RET fusion-positive non-small cell lung cancer in the phase Ⅰ/Ⅱ LIBRETTO-001 trial[J]. Oncologist, 2022, 27(1): 22-29. DOI: 10.1002/onco.13976.
[26]	Lu S, Cheng Y, Huang D, et al. Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase Ⅱ clinical trial (LIBRETTO-321)[J]. Ther Adv Med Oncol, 2022, 14: 17588359221105020. DOI: 10.1177/17588359221105020.
[27]	Cheng Y, Huang D, Zhou J, et al. Intracranial activity of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer in the phase Ⅱ LIBRETTO-321 trial[J]. JCO Precis Oncol, 2023, 7: e2200708. DOI: 10.1200/PO.22.00708.
[28]	Zhou C, Solomon B, Loong HH, et al. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC[J]. N Engl J Med, 2023, 389(20): 1839-1850. DOI: 10.1056/NEJMoa2309457.
[29]	Griesinger F, Curigliano G, Thomas M, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial[J]. Ann Oncol, 2022, 33(11): 1168-1178. DOI: 10.1016/j.annonc.2022.08.002. pmid: 35973665
[30]	Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study[J]. Lancet Oncol, 2021, 22(7): 959-969. DOI: 10.1016/S1470-2045(21)00247-3 pmid: 34118197
[31]	U.S. FOOD and Drug Administration. FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive non-small cell lung cancer[EB/OL]. (2022-09-21)[2025-01-19]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-non-small-cell-lung.
[32]	U.S. FOOD and Drug Administration. FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions[EB/OL]. (2023-08-09)[2025-01-19]. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pralsetinib-non-small-cell-lung-cancer-ret-gene-fusions.
[33]	国家食品药品监督管理局. 2022年10月09日药品批准证明文件待领取信息发布[EB/OL]. (2022-10-09)[2025-01-19]. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20221009160008139.html.
[34]	国家食品药品监督管理局. 2023年06月26日药品批准证明文件送达信息发布[EB/OL]. (2023-06-26)[2025-01-19]. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20230626133635185.html.
[35]	Solomon BJ, Tan L, Lin JJ, et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies[J]. J Thorac Oncol, 2020, 15(4): 541-549. DOI: 10.1016/j.jtho.2020.01.006.
[36]	Zhou Y, Xiang S, Yang F, et al. Targeting gatekeeper mutations for kinase drug discovery[J]. J Med Chem, 2022, 65(23): 15540-15558. DOI: 10.1021/acs.jmedchem.2c01361. pmid: 36395392
[37]	Wirth LJ, Kohno T, Udagawa H, et al. Emergence and targeting of acquired and hereditary resistance to multikinase RET inhibition in patients with RET-altered cancer[J]. JCO Precis Oncol, 2019, 3: PO. 19.00189. DOI: 10.1200/PO.19.00189.
[38]	Subbiah V, Shen T, Terzyan SS, et al. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations[J]. Ann Oncol, 2021, 32(2): 261-268. DOI: 10.1016/j.annonc.2020.10.599. pmid: 33161056
[39]	中国抗癌协会肿瘤精准治疗专业委员会, 中华医学会杂志社肺癌研究协作组, 中国临床肿瘤学会非小细胞肺癌专家委员会. 晚期RET融合阳性非小细胞肺癌诊疗中国专家共识(2023版)[J]. 中华肿瘤杂志, 2023, 45(12): 991-1002. DOI: 10.3760/cma.j.cn112152-20230711-00290.
[40]	Lin JJ, Liu SV, McCoach CE, et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer[J]. Ann Oncol, 2020, 31(12): 1725-1733. DOI: 10.1016/j.annonc.2020.09.015. pmid: 33007380
[41]	Rosen EY, Won HH, Zheng Y, et al. The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers[J]. Nat Commun, 2022, 13(1): 1450. DOI: 10.1038/s41467-022-28848-x.
[42]	Khatri U, Dayal N, Hu X, et al. Targeting RET solvent-front mutants with alkynyl nicotinamide-based inhibitors[J]. Mol Cancer Ther, 2023, 22(6): 717-725. DOI: 10.1158/1535-7163.MCT-22-0629.
[43]	Miyazaki I, Odintsov I, Ishida K, et al. Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations[J]. Nat Cancer, 2023, 4(9): 1345-1361. DOI: 10.1038/s43018-023-00630-y.
[44]	ClinicalTrials. gov. Phase Ⅰ/Ⅱ study of the selective RET inhibitor TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities[EB/OL]. (2020-12-16)[2025-01-19]. https://clinicaltrials.gov/study/NCT04683250.
[45]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2024[M]. 北京: 人民卫生出版社, 2024.